[1]Shi S, Tang Y, Zhao Q, et al. Prevalence and risk of atrial fibrillation in China: A national cross-sectional epidemiological study[J]. Lancet Reg Health West Pac, 2022, 23: 100439.doi: 10.1016/j.lanwpc.2022.100439. [2]中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2020概要[J]. 中国循环杂志, 2021, 36: 521-545. [3]张彬彬, 何涛, 吴娜, 等. 急性心肌梗死患者院内新发心房颤动的影响因素及其风险预测列线图模型构建[J]. 实用心脑肺血管病杂志, 2021, 29: 14-18. [4]张贵涛, 李淑娟. 心脑血管疾病研究前沿进展与热点[J]. 基础医学与临床, 2025, 45: 141. [5]Wang G, He Q, Shuai W, et al. The gut microbial metabolite phenylacetylglutamine increases susceptibility to atrial fibrillation after myocardial infarction through ferroptosis and NLRP3 inflammasome[J]. Apoptosis, 2025, 30: 210-225. [6]Qin Y, Zhao W. Posttranslational modifications of NLRP3 and their regulatory roles in inflammasome activation[J]. Eur J Immunol, 2023, 53: e2350382.doi:10.1002/eji.202350382. [7]Yang SB, Zhao H W. Associations between albumin/neutrophil-to-lymphocyte ratio score and new-onset atrial fibrillation in patients with acute myocardial infarction undergoing pCI[J]. J Inflamm Res, 2025, 18: 61-71. [8]Poppenborg T, Saljic A, Bruns F, et al. A short history of the atrial NLRP3 inflammasome and its distinct role in atrial fibrillation[J]. J Mol Cell Cardiol, 2025, 202: 13-23. [9]Boshchenko AA, Maslov LN, Mukhomedzyanov AV, et al. Peptides are cardioprotective drugs of the future: the receptor and signaling mechanisms of the cardioprotective effect of glucagon-like peptide-1 receptor agonists[J]. Int J Mol Sci, 2024, 25:4900.doi: 10.3390/ijms25094900. [10]Lee H, Rhee TM, Choi JM, et al. The close link between obesity and cardiovascular disease: current insights and remaining challenges[J]. Endocrinol Metab Clin North Am, 2025, 54: 175-192. [11]An X, Sun W, Wen Z, et al. Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis[J]. Diabetes Obes Metab, 2025, 27: 1735-1751. [12]Bohne LJ, Jansen HJ, Dorey TW, et al. Glucagon-like peptide-1 protects against atrial fibrillation and atrial remodeling in type 2 diabetic mice[J]. JACC Basic Transl Sci, 2023, 8: 922-936. [13]Le R, Nguyen MT, Allahwala MA, et al. Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs[J]. J Clin Med, 2024,13:4674. doi:10.3390/jcm13164674. [14]Wei H, Bu R, Yang Q, et al. Exendin-4 protects against hyperglycemia-induced cardiomyocyte pyroptosis via the AMPK-TXNIP pathway[J]. J Diabetes Res, 2019, 2019: 8905917. doi:10.1155/2019/8905917. [15]Meng S, Chen X, Zhao J, et al. Reduced FNDC5-AMPK signaling in diabetic atrium increases the susceptibility of atrial fibrillation by impairing mitochondrial dynamics and activating NLRP3 inflammasome[J]. Biochem Pharmacol, 2024, 229: 116476.doi: 10.1016/j.bcp.2024.116476. |